About Emergent Biosolutions (NYSE:EBS)
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Industry, Sector and Symbol
Trailing P/E Ratio31.8047337278107
Forward P/E Ratio23.10
Sales & Book Value
Annual Sales$560.87 million
Price / Sales4.75
Cash Flow$2.89 per share
Price / Cash18.61
Book Value$18.47 per share
Price / Book2.91
Net Income$82.59 million
Return on Equity13.66%
Return on Assets9.54%
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) released its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.70 by $0.04. The biopharmaceutical company had revenue of $193.80 million for the quarter, compared to analysts' expectations of $189.96 million. Emergent Biosolutions had a return on equity of 13.66% and a net margin of 14.73%. The business's quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 EPS. View Emergent Biosolutions' Earnings History.
When will Emergent Biosolutions make its next earnings announcement?
Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2018?
4 equities research analysts have issued 12-month price targets for Emergent Biosolutions' stock. Their predictions range from $43.00 to $60.00. On average, they expect Emergent Biosolutions' share price to reach $52.75 in the next twelve months. View Analyst Ratings for Emergent Biosolutions.
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Swedish Orphan Bio (SWTUY), AveXis (AVXS), Orion (ORINY), Integra Lifesciences (IART), Blueprint Medicines (BPMC), FibroGen (FGEN), Indivior (INVVY), ABLYNX (ABLYF), Taro Pharmaceutical Industries (TARO), Hikma Pharmaceutic (HKMPF), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Loxo Oncology (LOXO), Array Biopharma (ARRY), TESARO (TSRO) and ACADIA Pharmaceuticals (ACAD).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Fuad El-Hibri, Executive Chairman of the Board (Age 59)
- Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director (Age 57)
- Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer (Age 59)
- Adam Havey, Executive Vice President - Business Operations (Age 46)
- Ronald B. Richard, Lead Independent Director (Age 61)
- Sue Bailey M.D., Independent Director (Age 73)
- Zsolt Harsanyi Ph.D., Independent Director (Age 73)
- Jerome M. Hauer Ph.D., Independent Director (Age 65)
- George A. Joulwan USA, Independent Director (Age 77)
Has Emergent Biosolutions been receiving favorable news coverage?
Press coverage about EBS stock has trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Emergent Biosolutions earned a media sentiment score of 0.08 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.15%), Standard Life Aberdeen plc (3.57%), Renaissance Technologies LLC (3.21%), Acadian Asset Management LLC (3.49%), Snyder Capital Management L P (2.52%) and Glenmede Trust Co. NA (1.99%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which major investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Deutsche Bank AG, Wells Fargo & Company MN, Glenmede Trust Co. NA, BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Gotham Asset Management LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.
Which major investors are buying Emergent Biosolutions stock?
EBS stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Amundi Pioneer Asset Management Inc., OppenheimerFunds Inc., Fuller & Thaler Asset Management Inc., Snyder Capital Management L P, Rice Hall James & Associates LLC and Boston Advisors LLC. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $53.83.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $2.58 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.69 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (EBS)MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Emergent Biosolutions (NYSE:EBS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.67||2.67||2.67|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$52.75||$50.33||$45.00||$44.00|
|Price Target Upside: ||2.01% downside||0.96% downside||11.25% upside||45.94% upside|
Emergent Biosolutions (NYSE:EBS) Consensus Price Target History
Emergent Biosolutions (NYSE:EBS) Analyst Ratings History
(Data available from 3/21/2016 forward)
Emergent Biosolutions (NYSE:EBS) Earnings History and Estimates Chart
Emergent Biosolutions (NYSE EBS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/22/2018||Q4 2017||$0.70||$0.74||$189.96 million||$193.80 million||View||Listen|
|11/2/2017||Q3 2017||$0.41||$0.73||$124.55 million||$149.43 million||View||N/A|
|8/3/2017||Q2 2017||$0.26||$0.13||$111.57 million||$100.77 million||View||Listen|
|5/4/2017||Q1 2017||$0.31||$0.23||$121.30 million||$116.90 million||View||Listen|
|2/23/2017||Q4 2016||$0.48||$0.74||$120.45 million||$151.66 million||View||Listen|
|11/7/2016||Q3||$0.26||$0.58||$112.30 million||$142.91 million||View||Listen|
|8/4/2016||Q2||($0.17)||($0.18)||$111.20 million||$101.49 million||View||Listen|
|5/5/2016||Q1||($0.07)||$0.16||$101.83 million||$111.00 million||View||Listen|
|2/25/2016||Q4||$0.69||$0.78||$168.07 million||$168.10 million||View||Listen|
|11/5/2015||Q315||$0.55||$0.83||$151.42 million||$164.90 million||View||Listen|
|8/6/2015||Q215||$0.18||$0.36||$114.25 million||$126.10 million||View||Listen|
|5/7/2015||Q1||($0.46)||($0.50)||$62.70 million||$63.60 million||View||Listen|
|3/5/2015||Q115||$0.97||$0.75||$147.00 million||$148.00 million||View||Listen|
|11/6/2014||Q414||$0.37||$0.67||$126.90 million||$138.00 million||View||Listen|
|8/7/2014||Q214||$0.26||$0.24||$109.25 million||$110.30 million||View||Listen|
|5/8/2014||Q114||($0.34)||($0.40)||$57.30 million||$53.90 million||View||Listen|
|3/6/2014||Q413||$0.36||$0.42||$93.83 million||$94.10 million||View||Listen|
|11/7/2013||Q313||$0.21||$0.37||$79.13 million||$89.10 million||View||Listen|
|8/5/2013||Q2 2013||$0.21||$0.29||$75.73 million||$82.40 million||View||Listen|
|5/2/2013||Q1 2013||($0.14)||($0.22)||$46.17 million||$43.10 million||View||Listen|
|3/7/2013||Q4 2012||$0.44||$0.44||$95.09 million||$94.61 million||View||Listen|
|11/1/2012||Q312||$0.22||$0.18||$73.53 million||$66.60 million||View||N/A|
Emergent Biosolutions (NYSE:EBS) Earnings Estimates
Current Year EPS Consensus Estimate: $2.33 EPS
Next Year EPS Consensus Estimate: $3.03 EPS
Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com
Emergent Biosolutions (NYSE EBS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 81.54%
Emergent Biosolutions (NYSE EBS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/12/2018||Adam Havey||EVP||Sell||5,842||$52.82||$308,574.44||35,756|| |
|3/1/2018||Adam Havey||EVP||Sell||1,898||$49.50||$93,951.00|| |
|1/22/2018||Jerome M Hauer||Director||Sell||5,152||$50.91||$262,288.32||23,797|| |
|1/2/2018||Daniel Abdun-Nabi||CEO||Sell||21,906||$47.91||$1,049,516.46||226,040|| |
|12/13/2017||Daniel Abdun-Nabi||CEO||Sell||20,000||$45.99||$919,800.00||224,134|| |
|12/12/2017||Ronald Richard||Director||Sell||23,681||$45.02||$1,066,118.62||47,091|| |
|12/7/2017||Zsolt Harsanyi||Director||Sell||7,000||$42.47||$297,290.00||37,077|| |
|11/29/2017||Fuad El-Hibri||Chairman||Sell||47,983||$41.88||$2,009,528.04||1,550,216|| |
|11/14/2017||Fuad El-Hibri||Chairman||Sell||40,000||$40.37||$1,614,800.00|| |
|11/7/2017||George A Joulwan||Director||Sell||14,251||$41.24||$587,711.24||34,323|| |
|11/3/2017||Daniel Abdun-Nabi||CEO||Sell||31,508||$42.77||$1,347,597.16||215,642|| |
|9/29/2017||Fuad El-Hibri||Chairman||Sell||25,000||$40.50||$1,012,500.00||1,555,216|| |
|9/28/2017||Ronald Richard||Director||Sell||22,415||$40.00||$896,600.00||24,676|| |
|9/27/2017||Adam Havey||EVP||Sell||7,885||$39.50||$311,457.50||33,931|| |
|9/27/2017||Daniel Abdun-Nabi||CEO||Sell||15,000||$39.92||$598,800.00||219,134|| |
|9/27/2017||Fuad El-Hibri||Chairman||Sell||25,000||$39.50||$987,500.00||1,555,216|| |
|9/27/2017||Ronald Richard||Director||Sell||1,266||$40.00||$50,640.00||24,676|| |
|9/14/2017||Fuad El-Hibri||Chairman||Sell||25,000||$38.50||$962,500.00||1,603,763|| |
|9/8/2017||Adam Havey||EVP||Sell||7,885||$37.06||$292,218.10||33,931|| |
|9/7/2017||Fuad El-Hibri||Chairman||Sell||16,439||$37.50||$616,462.50||1,605,216|| |
|9/5/2017||Fuad El-Hibri||Chairman||Sell||3,100||$37.50||$116,250.00||1,621,655|| |
|8/31/2017||Daniel Abdun-Nabi||CEO||Sell||15,000||$37.21||$558,150.00||219,134|| |
|8/31/2017||Fuad El-Hibri||Chairman||Sell||5,461||$37.50||$204,787.50||1,624,755|| |
|8/15/2017||Jerome M Hauer||Director||Sell||10,776||$35.83||$386,104.08||29,421|| |
|7/27/2017||Fuad El-Hibri||Chairman||Sell||25,000||$36.50||$912,500.00||1,630,216|| |
|7/20/2017||Fuad El-Hibri||Chairman||Sell||25,000||$35.50||$887,500.00||1,655,216|| |
|4/3/2017||Adam Havey||EVP||Sell||11,419||$28.62||$326,811.78||26,046|| |
|3/8/2017||Jerome M Hauer||Director||Sell||2,576||$31.27||$80,551.52||17,404|| |
|1/17/2017||Adam Havey||EVP||Sell||8,438||$29.75||$251,030.50||41,424|| |
|1/17/2017||Sue Bailey||Director||Sell||19,424||$29.78||$578,446.72||34,637|| |
|1/10/2017||Daniel Abdun-Nabi||Insider||Sell||28,240||$31.28||$883,347.20||172,945|| |
|12/13/2016||Ronald Richard||Director||Sell||5,900||$34.09||$201,131.00||19,870|| |
|6/6/2016||George A Joulwan||Director||Sell||4,700||$44.12||$207,364.00||20,785|| |
|6/1/2016||Daniel Abdun-Nabi||CEO||Sell||8,699||$43.74||$380,494.26||170,966|| |
|5/27/2016||Fuad El-Hibri||Major Shareholder||Sell||9,835||$43.50||$427,822.50||1,649,073|| |
|5/26/2016||Fuad El-Hibri||Major Shareholder||Sell||39,759||$43.13||$1,714,805.67||1,698,667|| |
|5/25/2016||Fuad El-Hibri||Major Shareholder||Sell||85,000||$42.52||$3,614,200.00||1,719,073|| |
|5/25/2016||Zsolt Harsanyi||Director||Sell||27,867||$42.33||$1,179,610.11||41,685|| |
|5/24/2016||Fuad El-Hibri||Chairman||Sell||20,000||$42.26||$845,200.00||1,719,073|| |
|5/23/2016||Fuad El-Hibri||Chairman||Sell||45,000||$42.62||$1,917,900.00||1,719,073|| |
|5/20/2016||Daniel Abdun-Nabi||CEO||Sell||8,701||$42.00||$365,442.00||179,665|| |
|5/19/2016||Jerome M Hauer||Director||Sell||3,134||$41.22||$129,183.48||20,085|| |
|5/13/2016||Louis W Sullivan||Director||Sell||47,631||$39.21||$1,867,611.51||28,800|| |
|5/12/2016||Fuad El-Hibri||Major Shareholder||Sell||25,000||$38.71||$967,750.00||1,699,073|| |
|5/12/2016||Jerome M Hauer||Director||Sell||4,700||$38.50||$180,950.00||18,800|| |
|5/11/2016||Louis W Sullivan||Director||Sell||9,969||$39.25||$391,283.25||38,469|| |
|4/22/2016||Fuad El-Hibri||Major Shareholder||Sell||4,209||$40.50||$170,464.50||1,724,073|| |
|4/18/2016||Daniel Abdun-Nabi||CEO||Sell||8,702||$40.17||$349,559.34||194,319|| |
|4/18/2016||Fuad El-Hibri||Major Shareholder||Sell||20,791||$40.50||$842,035.50||1,728,282|| |
|4/6/2016||Fuad El-Hibri||Major Shareholder||Sell||50,000||$39.00||$1,950,000.00||1,774,073|| |
|4/6/2016||Robert Kramer||EVP||Sell||21,786||$38.90||$847,475.40||77,551|| |
|4/4/2016||Robert Kramer||EVP||Sell||21,788||$36.90||$803,977.20||80,597|| |
|4/1/2016||Robert Kramer||EVP||Sell||43,572||$35.56||$1,549,420.32||91,607|| |
|3/14/2016||Adam Havey||EVP||Sell||4,359||$33.96||$148,031.64||39,163|| |
|3/14/2016||Jerome M Hauer||Director||Sell||2,350||$33.88||$79,618.00||14,100|| |
|3/11/2016||Adam Havey||EVP||Sell||11,112||$33.84||$376,030.08||54,254|| |
|3/11/2016||Louis W Sullivan||Director||Sell||14,879||$34.03||$506,332.37||43,379|| |
|3/7/2016||Marvin L White||Director||Sell||33,134||$35.42||$1,173,606.28||41,100|| |
|1/4/2016||Sue Bailey||Director||Sell||11,520||$38.79||$446,860.80||28,500|| |
|12/30/2015||Ronald Richard||Director||Sell||21,600||$40.00||$864,000.00||13,733|| |
|12/24/2015||Daniel Abdun-Nabi||CEO||Sell||63,209||$39.06||$2,468,943.54||185,368|| |
|11/19/2015||Fuad El-Hibri||major shareholder||Sell||17,871||$37.50||$670,162.50||1,852,284|| |
|11/13/2015||Fuad El-Hibri||major shareholder||Sell||13,013||$36.50||$474,974.50||1,842,255|| |
|11/12/2015||Barry Labinger||EVP||Sell||36,126||$35.64||$1,287,530.64||28,558|| |
|11/9/2015||Fuad El-Hibri||major shareholder||Sell||13,225||$35.50||$469,487.50||1,835,268|| |
|11/6/2015||Fuad El-Hibri||major shareholder||Sell||13,450||$34.50||$464,025.00||1,828,493|| |
|11/3/2015||Fuad El-Hibri||major shareholder||Sell||13,689||$33.50||$458,581.50||1,821,943|| |
|9/11/2015||Sue Bailey||Director||Sell||6,080||$32.37||$196,809.60||28,500|| |
|8/13/2015||George A Joulwan||Director||Sell||7,200||$34.72||$249,984.00|| |
|7/20/2015||Fuad El-Hibri||Chairman||Sell||234||$34.50||$8,073.00|| |
|7/13/2015||Ronald Richard||Director||Sell||4,922||$34.00||$167,348.00|| |
|6/29/2015||Ronald Richard||Director||Sell||4,923||$32.76||$161,277.48|| |
|6/22/2015||Fuad El-Hibri||Major Shareholder||Sell||74,564||$32.60||$2,430,786.40|| |
|6/16/2015||Louis W Sullivan||Director||Sell||13,457||$31.33||$421,607.81|| |
|6/15/2015||Adam Havey||EVP||Sell||36,298||$31.55||$1,145,201.90|| |
|6/15/2015||Fuad El-Hibri||Major Shareholder||Sell||45,436||$32.18||$1,462,130.48|| |
|1/20/2015||Fuad El-Hibri||Major Shareholder||Sell||15,325||$27.67||$424,042.75|| |
|12/26/2014||Ronald Richard||Director||Sell||5,000||$28.00||$140,000.00|| |
|12/17/2014||Ronald Richard||Director||Sell||5,000||$27.00||$135,000.00|| |
|12/11/2014||Fuad El-Hibri||Major Shareholder||Sell||119,341||$26.00||$3,102,866.00|| |
|11/28/2014||Fuad El-Hibri||Major Shareholder||Sell||34,577||$25.00||$864,425.00|| |
|11/25/2014||Fuad El-Hibri||Major Shareholder||Sell||9,014||$25.00||$225,350.00|| |
|11/25/2014||Zsolt Harsanyi||Director||Sell||8,000||$24.82||$198,560.00|| |
|11/12/2014||Fuad El-Hibri||Major Shareholder||Sell||2,311||$25.00||$57,775.00|| |
|11/7/2014||Robert Kramer||CFO||Sell||2,625||$24.00||$63,000.00|| |
|4/16/2014||Robert Kramer||CFO||Sell||50,189||$24.34||$1,221,600.26||62,183|| |
|3/12/2014||Adam Havey||EVP||Sell||11,562||$27.50||$317,955.00||36,145|| |
|3/11/2014||Adam Havey||EVP||Sell||17,655||$26.96||$475,978.80||36,920|| |
Emergent Biosolutions (NYSE EBS) News Headlines
Emergent Biosolutions (NYSE:EBS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Emergent Biosolutions (NYSE:EBS) Income Statement, Balance Sheet and Cash Flow Statement
Emergent Biosolutions (NYSE EBS) Stock Chart for Wednesday, March, 21, 2018